Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2554708 | Life Sciences | 2006 | 9 Pages |
Abstract
Palmitoylethanolamide (200 μg/mouse i.p) also reduced the response to compound 48/80, whereas no firm conclusions could be drawn for palmitoylisopropylamide (20 and 200 μg/mouse i.p.). The CB2 selective antagonist/inverse agonist SR144528 (60 μg/mouse i.p.) appeared to produce anti-inflammatory effects per se in this model, making it hard to interpret the effects of JWH133 in terms of CB2 receptor mediated activation. In contrast to the situation in vivo, neither JWH133 (0.3 and 3 μM) nor palmitoylethanolamide (10 μM) affected mast cell degranulation, measured by following the release of the granular protein β-hexosaminidase, produced by compound 48/80 in vitro in mouse skin slices. The two compounds were also ineffective in inhibiting the binding of [3H]pyrilamine to histamine H1 receptors in vitro. It is concluded that the ability of JWH133 to affect mast cell dependent inflammation in vivo may be mediated by an indirect action upon the mast cells.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kent-Olov Jonsson, Emma Persson, Christopher J. Fowler,